Spots Global Cancer Trial Database for Contributions to Hypertension With Androgen Deprivation Therapy
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Contributions to Hypertension With Androgen Deprivation Therapy
Official Title: Autonomic and Renal Contributions to Hypertension With Androgen Deprivation Therapy
Study ID: NCT05700903
Study Description
Brief Summary: This study plans to learn more about contributors to high blood pressure in men who undergo androgen deprivation therapy (ADT) to treat prostate cancer. Prostate cancer is the most common non-skin cancer in men, affecting approximately 1 in 8 American men and its primary treatment is through the use of ADT. However, ADT increases the likelihood of developing heart disease including high blood pressure. This study will determine if dysfunction of the nervous system and/or kidneys occurs in men undergoing ADT, as these systems play a significant role in control of blood pressure. The results from this study will help us understand the ways in which ADT contributes to heart disease and help us develop therapies to prevent heart disease in prostate cancer survivors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: Yes
Locations
UCHealth University of Colorado Hospital, Aurora, Colorado, United States
Contact Details
Name: Matthew Babcock, PhD
Affiliation: University of Colorado - Anschutz Medical Campus
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
